UAE The UAE ranks among the world’s fastest for new drug approvals, ranking first for two cancer drugs and second for many others, such as blockbuster melanoma drug Keytruda. The Ministry of Health and Prevention of the United Arab Emirates (MOHAP) has enhanced its processes by implementing an electronic registration system,…
UAE The UAE ranks as a world leader in rapid drug approvals with its fast-track registration system that accelerates the process and eliminates long waiting times for innovative and orphan drugs. If you bring innovation, the [UAE] government will support you on all levels Georg Schroeckenfuchs, Novartis In January 2018…
China China’s new Amended Drug Administration Law is being enacted to strengthen and streamline its regulation of the pharmaceutical industry as well as address prominent problems such as counterfeit drugs, substandard drugs and high drug prices. Fangda Partners’ Josh Shin explains how the new law strengthens penalties for counterfeit and substandard…
4+7 China’s roll-out of a 25-province expansion to the 4+7 pilot procurement scheme has seen pharma companies scrambling to cut prices for their drugs even further in the latest bidding war. Pharma companies in China are facing yet another intense race to the bottom on pricing. On the 24th of…
China Eric Bouteiller outlines the paradigm shift occurring in China around rare diseases and how the country has the potential to lead the global pharmaceutical industry in this vital area. Through exchanges with public officials, academics, representatives of patient associations and industry experts, we sensed a paradigm shift The 8th…
Taiwan Today Su, CEO of Golden Biotechnology, introduces the innovative biotech developing a revolutionary botanical drug derived from the Taiwanese fungus Antrodia Camphorata. The company’s drug, Hocena®, has already received several orphan drug designations and thus far has exhibited promising results in key indications such as pancreatic cancer, non-small cell lung…
AI Arthur Kadurin, CEO of Insilico Medicine Taiwan, tells us how artificial intelligence can change drug discovery process using the innovative generative adversarial networks (GANs) approach. AI is the future of the industry that has all the potential to transform and combat the complex drug discovery process. Please tell us…
Opinion Kevin Rufang Huang is the president and founder of the Chinese Organization for Rare Disorders (CORD). A rare disease patient himself, he is responsible for bringing“International Rare Disease Day” to China. Consequently, rare diseases now have much more visibility in the country. As an expert on the subject, Kevin breaks…
Rare Diseases Long regarded as a neglected backwater within the drug discovery landscape and the preserve of only a handful of niche players, the rare disease space has been undergoing an extraordinary turnaround in fortunes of late. According to EvaluatePharma’s forecasts, orphan drug sales are set to grow 11 percent each…
Rare Diseases The 28th February 2019, marks the twelfth international Rare Disease Day. On and around this day hundreds of patient organisations from countries and regions across the globe will strive to raise awareness of some of the world’s rarest disease. For many of the rare diseases out there, we are yet to…
South Korea This week the Korean Ministry of Food and Drug Safety announced that as of 12th March 2019 a revised narcotics bill will go into effect that will allow imports of medical cannabis for self-treatment but under strict conditions. Until now, the import, export, manufacturing and sale of cannabis has been…
Top 10 The Top 10 bestselling orphan drugs in the USA in 2017. Celgene’s Revlimid (generic name lenolidamide) leads the way with sales of USD 5.4 billion, followed by Roche’s Rituxan (rituximab) with USD 4.2 billion in sales and TEVA’s Copaxone (glatiramer acetate) with USD 3.1 billion. The most expensive drug in…
See our Cookie Privacy Policy Here